|
Dr. Bartus has over 30 years of experience in the pharmaceutical and biotech industries, involving tenures both at major multi-national companies and smaller, development-stage companies. Dr. Bartus joined Ceregene in December, 2002 and directs all preclinical, clinical and regulatory activities as well as chairs the company's SAB meetings. Prior to joining Ceregene, Dr. Bartus spent 10 years at Alkermes, where he served as Senior Vice President for Preclinical Research and Development. During his tenure at Alkermes, he was directly responsible for the conceptualization, preclinical development and initial clinical strategy for Alkermes' lead proprietary product, Vivitrol (formally called Vivitrex), which has since gained FDA approval. Dr. Bartus was selected to launch and served as Chief Editor for the scholarly journal Neurobiology of Aging. During his 10 years as Chief Editor, it grew to rank as the leading specialized journal in its field. He has also been selected to serve on numerous panels and "think tanks", including for the U.S. Congress' Office of Technology Assessment, Secretary of Health and Human Services, and FDA, among others. He is recognized as one of the founders of the 'Cholinergic Hypothesis', a hypothesis that led directly to the first four drugs approved by the FDA for Alzheimer's disease. He has been honored by ISI (the Institute for Scientific Information) as a "highly cited" researcher, comprising less than 0.5% of all publishing scientists. In addition to helping discover and develop several novel therapies for human diseases, Dr. Bartus has published nearly 250 scholarly papers, chapters, books and special journal issues. | 